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Gliomas are the most common primary tumors of 
the central nervous system, accounting for the majority 
of adult primary brain tumors [1]. One of the major 
pathophysiological features of malignant human gliomas 
is their ability to diffusely and deeply invade into 
surrounding brain tissues [2-4]. The invasive phenotype 
is acquired early during glioma progression; even in low 
grade tumors, single or small groups of cells detach from 
the original site, attach to and remodel the extracellular 
matrix (ECM) during their migration, and penetrate 
and destroy adjacent brain structures [5]. The diffusely 
infiltrative nature of gliomas is believed to underlie tumor 
recurrence after surgery; therefore, understanding the 
mechanisms of glioma invasiveness and their response to 
therapy are very important.
To investigate these processes, initial work has 
focused on tumor-ECM interactions. The invasive 
process of glioma cells requires changes in the adhesive 
properties of the cells and expression of proteases. 
Neural cell adhesion molecules [6] and E-cadherin [7] 
are downregulated, while CD44 [8] and N-cadherin [7, 
9, 10] are upregulated. Attachment to ECM involves 
integrins such as β1-integrin [11-13] and tenascin-C 
[14]. ECM remodeling is accomplished via the action 
of several classes of proteases including matrix 
metalloproteinases (MMPs), [2], ADAMs (a disintegrin 
and metalloproteinase), plasmin and cathepsins (2). 
Invasion also requires cytoskeletal rearrangements, 
formation of focal adhesions and lamellipodia involving 
Rho and Rac [15]. 
The human Angiopoietin /Tie system plays a crucial 
role in the remodeling of the tumor microenvironment that 
accompanies the angiogenic switch in tumors, in order to 
control endothelial cell survival and vascular maturation 
and thereby promoting tumor growth. 
The Angiopoietin family includes four ligands 
(Angiopoietins-1, 2, 3 and 4). The best characterized are 
Ang1 and 2, while the role of Ang3 and Ang4 are less well 
known. These ligands bind to the Tie1 and Tie2 tyrosine 
kinase receptors. Tie2 is well studied and expressed by 
endothelial cells, hematopoietic cells and tumor cells, 
and binds both Ang-1 and Ang-2 with similar affinity. In 
contrast, Tie1 is an orphan receptor, exclusively expressed 
by endothelial cells (ECs) whose role is incompletely 
defined [16].
Ang-1, secreted by perivascular cells and pericytes, 
acts in a paracrine agonistic manner and induces 
endothelial Tie2 phosphorylation and subsequent vessel 
stabilization. Ang1 binding to Tie2 results in receptor 
dimerization, which stimulates autophosphorylation 
of the Tie2 kinase domain [17], and triggers survival 
signaling in resting ECs by activating PI3kinase/AKT 
[18]. The signaling through PI3kinase promotes Ang1-
induced cell survival, control of vascular permeability 
and regulates the capillary sprouting that occurs during 
normal and tumoral angiogenesis [19].
In contrast, Ang-2 acts as an antagonist of Ang-1-
mediated Tie2 activation. Autocrine production of Ang-
2 by endothelial cells serves as a rheostat to control the 
level of Tie2 phosphorylation by Ang1. Ang2 modulates 
the vascular remodeling occurring during angiogenesis 
in a cooperative manner with pro-angiogenic factors 
including vascular endothelial growth factor-A (VEGF-A) 
[20]. Ang2 dose-dependently inhibits Ang1-induced Tie2 
phosphorylation, Akt activation, EC survival [21], and 
induces vessel destabilization and pericyte dropout at 
higher concentration. Ang-2 is strongly expressed in the 
vasculature of many tumors where it is believed to act 
synergistically with pro-angiogenic cytokines and promote Oncotarget 2011; 2:  1 - 4 2 www.impactjournals.com/oncotarget
tumor-associated angiogenesis and tumor progression. 
The elevation of expression of VEGF and Ang2 is believed 
to play a key role in the pseudopalisading necrosis and 
associated glomeruloid microvascular proliferation that 
are pathognomonic features of glioblastomas [22-24].
Although Tie2 was originally described as a specific 
receptor for endothelium, its expression has been reported 
in nonvascular normal and neoplastic tissues [12, 25, 26]. 
Tie2 was found expressed by hematopoietic stem cells 
[27], and in gastric [28], thyroid [29] and breast cancers 
[30]. The expression of Tie2 is particularly high in glioma 
as compared to normal brain tissue, and increases with 
the progression from low to high grade gliomas [12]. Tie2 
activation can modify the adhesion properties of glioma 
cells by increasing their binding to ECM components 
such as collagen type I and IV through the induction of 
the expression of β1-integrin [12], similar to observations 
in hematopoietic stem cells [27]. 
A new study by Liu et al [31] in the recent December 
issue of Oncotarget broadens our knowledge of glioma 
cell invasion to interactions with other cells in the tumor 
environment. They propose that Tie2/Ang1 promotes 
the invasion phenotype by modulating the interaction 
of glioma and brain tumor stem like cells (BTSC) with 
endothelial cells. This cooperation was evidenced when 
Tie2-positive tumor cells were co-injected with endothelial 
cells in brains of immunocompromised mice. The tumor 
cells migrated farther from the injection site, developed 
multifocal tumors surrounding vascular structures and 
tended to be more aggressive than Tie2 negative-tumors. 
They determined that Ang1-mediated Tie2 activation in 
glioma cells and BTSCs enhances their adhesion to human 
umbilical vein endothelial cells in vitro. The mechanism 
underlying the latter effects involves the upregulation of 
β1-integrin  and  N-cadherin  (Fig.1).  While  VEGF  may 
regulate endothelial cell-cell or cell-matrix interactions 
[32], they found Ang1/Tie2 mediated adhesion to be 
VEGF independent. Tie2 also increased the tumor cells’ 
autonomous invasion capabilities in a 3D matrix, but 
unfortunately, the influence of endothelial cells was not 
proposed that heterotypic cell contact/communication 
between cancer cells and adjacent vascular cells can boost 
Fig 1: Tie2 activation enhances the interaction of glioma and brain tumor stem-like cells with endothelial cells and 
promotes their invasive phenotype. Angiopoietin1 (Ang1)  present in the extracellular matrix activates Tie2 that is  expressed by glioma 
and brain tumor stem-like cells (BTSC) and thereby upregulates β1−integrin and N-cadherin. This upregulation increases cancer- endothelial 
cell interactions, which promote tumor cells to invade healthy  brain tissue. Ang2 acts as antagonist of Ang1 and prevents Tie2 receptor 
activation.
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the tumor invasive phenotype and thereby malignancy. 
These findings provide new insights on how expression of 
Tie2 on tumor cells is translated into a highly infiltrative 
phenotype in human gliomas.
The  in vivo tumor phenomenon observed by Liu 
et al [31] is intriguing and raises further questions. How 
do  tumor  cells  more  efficiently  invade  normal  brain 
tissue and establish tumor foci when they coexist with 
endothelial cells? Does this phenomenon require tumor 
cells to bind to and co-migrate with endothelial cells? 
Are endothelial cells providing paracrine pro-migratory 
or pro-survival signals for cancer stem-like cells? Do the 
endothelial cells participate in accelerating the formation 
of a vascular supply to the tumor? Clearly, the effect is 
Tie2-dependent, as it was not observed in parental tumor 
cells mixed with endothelial cells. A demonstration of this 
effect with brain endothelial cells and a careful analysis 
of their presence in clusters of migrating Tie-2- positive 
glioma cells and alteration of N-cadherin and β1-integrin 
should help answer this question and provide a link with 
the in vitro findings on adhesion. 
What  do  these  novel  findings  mean  for  therapy? 
Since this increase in malignancy of glioma cells is 
associated with Tie2 expression, the obvious strategy 
is to target the signaling emanating from Tie2 upon 
angiopoietin activation. A handful of drugs targeting Tie2 
tyrosine kinase are under clinical evaluation (CEP-11981, 
CE-245677 and AMG-386). Another clinically relevant 
question is whether changes in the invasive phenotype seen 
in tumors of patients treated with anti-VEGF antibodies 
(Bevacizumab), are related to Tie2 upregulation and this 
VEGF-independent invasive mechanism. The results of 
the clinical trials conducted with these agents and a deeper 
mechanistic understanding of glioma–endothelial cell 
communication in invasion will significantly extend this 
knowledge to more effective clinical translation for the 
treatment of glioblastoma patients. We eagerly anticipate 
more to unfold in this interesting (com)plot.
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